Pages that link to "Item:Q3079137"

The following pages link to Dose-Finding with Two Agents in Phase I Oncology Trials (Q3079137):

Displaying 20 items.

• Bayesian phase I/II adaptively randomized oncology trials with combined drugs (Q641145) (← links)
• Stochastic approximation and modern model-based designs for dose-finding clinical trials (Q903289) (← links)
• Bayesian models and decision algorithms for complex early phase clinical trials (Q903294) (← links)
• A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate (Q1733138) (← links)
• Analysis of ``learn-as-you-go'' (LAGO) studies (Q2039787) (← links)
• A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-tapering (Q2170396) (← links)
• Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
• Adaptive designs for selecting drug combinations based on efficacy-toxicity response (Q2475724) (← links)
• Continual Reassessment Method for Partial Ordering (Q2893418) (← links)
• A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents (Q3064270) (← links)
• A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents (Q3183236) (← links)
• Designs for Single- or Multiple-Agent Phase I Trials (Q3445286) (← links)
• Determining the Effective Sample Size of a Parametric Prior (Q3506509) (← links)
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials (Q3576931) (← links)
• Semiparametric Dose Finding Methods for Partially Ordered Drug Combinations (Q5041342) (← links)
• Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials (Q5050425) (← links)
• A Parallel Phase I/II Clinical Trial Design for Combination Therapies (Q5459586) (← links)
• Two‐Dimensional Dose Finding in Discrete Dose Space (Q5715373) (← links)
• Flexible use of copula‐type model for dose‐finding in drug combination clinical trials (Q6055718) (← links)
• Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information (Q6085905) (← links)